Clariant
Market Cap
CHF6.3b
Last Updated
2021/04/11 17:13 UTC
Data Sources
Company Financials +
Executive Summary
Clariant AG, together with its subsidiaries, develops, manufactures, distributes, and sells specialty chemicals worldwide. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with reasonable growth potential.
Similar Companies
Share Price & News
How has Clariant's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CLN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: CLN's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
-1.0%
CLN
1.2%
CH Chemicals
1.1%
CH Market
1 Year Return
5.7%
CLN
40.7%
CH Chemicals
21.5%
CH Market
Return vs Industry: CLN underperformed the Swiss Chemicals industry which returned 40.7% over the past year.
Return vs Market: CLN underperformed the Swiss Market which returned 21.5% over the past year.
Shareholder returns
| CLN | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.0% | 1.2% | 1.1% |
| 30 Day | -3.9% | 4.1% | 3.7% |
| 90 Day | -1.0% | 3.4% | 5.7% |
| 1 Year | 24.2%5.7% | 44.8%40.7% | 25.2%21.5% |
| 3 Year | -4.1%-20.4% | 63.3%49.1% | 35.5%19.5% |
| 5 Year | 44.9%12.1% | 108.1%79.7% | 61.3%32.1% |
Long-Term Price Volatility Vs. Market
How volatile is Clariant's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
What Is The Ownership Structure Like For Clariant AG (VTX:CLN)?1 month ago | Simply Wall St
Does Clariant AG's (VTX:CLN) Weak Fundamentals Mean That The Stock Could Move In The Opposite Direction?2 months ago | Simply Wall St
A Look At Clariant's (VTX:CLN) Share Price ReturnsValuation
Is Clariant undervalued compared to its fair value and its price relative to the market?
18.7%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CLN (CHF19.07) is trading below our estimate of fair value (CHF23.47)
Significantly Below Fair Value: CLN is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: CLN is poor value based on its PE Ratio (83.8x) compared to the CH Chemicals industry average (47.3x).
PE vs Market: CLN is poor value based on its PE Ratio (83.8x) compared to the Swiss market (24.8x).
Price to Earnings Growth Ratio
PEG Ratio: CLN is poor value based on its PEG Ratio (3.3x)
Price to Book Ratio
PB vs Industry: CLN is good value based on its PB Ratio (2.8x) compared to the CH Chemicals industry average (6.6x).
Future Growth
How is Clariant forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
25.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLN's forecast earnings growth (25.2% per year) is above the savings rate (-0.3%).
Earnings vs Market: CLN's earnings (25.2% per year) are forecast to grow faster than the Swiss market (13.5% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CLN's revenue (4.9% per year) is forecast to grow faster than the Swiss market (4.6% per year).
High Growth Revenue: CLN's revenue (4.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CLN's Return on Equity is forecast to be low in 3 years time (12.1%).
Past Performance
How has Clariant performed over the past 5 years?
-25.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CLN has a large one-off loss of CHF119.0M impacting its December 31 2020 financial results.
Growing Profit Margin: CLN became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: CLN's earnings have declined by 25.7% per year over the past 5 years.
Accelerating Growth: CLN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CLN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Chemicals industry (5.8%).
Return on Equity
High ROE: CLN's Return on Equity (4.9%) is considered low.
Financial Health
How is Clariant's financial position?
Financial Position Analysis
Short Term Liabilities: CLN's short term assets (CHF3.3B) exceed its short term liabilities (CHF2.1B).
Long Term Liabilities: CLN's short term assets (CHF3.3B) exceed its long term liabilities (CHF2.5B).
Debt to Equity History and Analysis
Debt Level: CLN's debt to equity ratio (76.5%) is considered high.
Reducing Debt: CLN's debt to equity ratio has reduced from 90.7% to 76.5% over the past 5 years.
Debt Coverage: CLN's debt is well covered by operating cash flow (20.3%).
Interest Coverage: CLN's interest payments on its debt are well covered by EBIT (4.3x coverage).
Balance Sheet
Dividend
What is Clariant current dividend yield, its reliability and sustainability?
0.79%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: CLN's dividend (0.79%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.5%).
High Dividend: CLN's dividend (0.79%) is low compared to the top 25% of dividend payers in the Swiss market (3.49%).
Stability and Growth of Payments
Stable Dividend: CLN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are stable.
Growing Dividend: CLN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: CLN is not paying a notable dividend for the Swiss market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CLN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.4yrs
Average management tenure
CEO
Conrad Keijzer (52 yo)
0.25
Tenure
Mr. Conrad Keijzer has been Chief Executive Officer at Clariant AG since January 01, 2021. He served as Chief Executive Officer & Director of IMERYS since May 04, 2018 until October 2019. He was Deputy Chi...
Leadership Team
Experienced Management: CLN's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
Experienced Board: CLN's board of directors are considered experienced (3.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Clariant AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Clariant AG
- Ticker: CLN
- Exchange: SWX
- Founded: 1886
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: CHF6.285b
- Shares outstanding: 329.55m
- Website: https://www.clariant.com
Number of Employees
Location
- Clariant AG
- Rothausstrasse 61
- Muttenz
- Basel-Landschaft
- 4132
- Switzerland
Listings
Biography
Clariant AG, together with its subsidiaries, develops, manufactures, distributes, and sells specialty chemicals worldwide. It operates in three segments: Care Chemicals, Catalysis, Natural Resources. The c...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/11 17:13 |
| End of Day Share Price | 2021/04/09 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.